Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

OBE022, an Oral and Selective Prostaglandin F2α Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor.

Pohl O, Chollet A, Kim SH, Riaposova L, Spézia F, Gervais F, Guillaume P, Lluel P, Méen M, Lemaux F, Terzidou V, Bennett PR, Gotteland JP.

J Pharmacol Exp Ther. 2018 Aug;366(2):349-364. doi: 10.1124/jpet.118.247668. Epub 2018 May 18.

PMID:
29777040
2.

Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women.

Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U.

Br J Clin Pharmacol. 2018 Aug;84(8):1839-1855. doi: 10.1111/bcp.13622. Epub 2018 Jun 5.

PMID:
29708281
3.

Confirmation of the Cardiac Safety of PGF Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments.

Täubel J, Lorch U, Coates S, Fernandes S, Foley P, Ferber G, Gotteland JP, Pohl O.

Clin Pharmacol Drug Dev. 2018 Feb 28. doi: 10.1002/cpdd.447. [Epub ahead of print]

PMID:
29489066
4.

Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109.

Pohl O, Marchand L, Fawkes N, Gotteland JP, Loumaye E.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):497-504. doi: 10.1210/jc.2017-01875.

PMID:
29216361
5.

Differential Effects of Oxytocin Receptor Antagonists, Atosiban and Nolasiban, on Oxytocin Receptor-Mediated Signaling in Human Amnion and Myometrium.

Kim SH, Pohl O, Chollet A, Gotteland JP, Fairhurst AD, Bennett PR, Terzidou V.

Mol Pharmacol. 2017 Apr;91(4):403-415. doi: 10.1124/mol.116.106013. Epub 2017 Feb 10.

6.

c-Jun NH2-terminal kinase inhibitor bentamapimod reduces induced endometriosis in baboons: an assessor-blind placebo-controlled randomized study.

Hussein M, Chai DC, Kyama CM, Mwenda JM, Palmer SS, Gotteland JP, D'Hooghe TM.

Fertil Steril. 2016 Mar;105(3):815-824.e5. doi: 10.1016/j.fertnstert.2015.11.022. Epub 2015 Dec 2.

PMID:
26654972
7.

Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models.

Palmer SS, Altan M, Denis D, Tos EG, Gotteland JP, Osteen KG, Bruner-Tran KL, Nataraja SG.

Reprod Sci. 2016 Jan;23(1):11-23. doi: 10.1177/1933719115600553. Epub 2015 Sep 2.

8.

The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.

Pohl O, Zobrist RH, Gotteland JP.

Reprod Sci. 2015 Apr;22(4):476-83. doi: 10.1177/1933719114549850. Epub 2014 Sep 16. Review.

9.

Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age.

Pohl O, Bestel E, Gotteland JP.

Reprod Sci. 2014 Oct;21(10):1256-65. doi: 10.1177/1933719114522526. Epub 2014 Mar 6.

PMID:
24604234
10.

Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate.

Pohl O, Osterloh I, Gotteland JP.

J Clin Pharm Ther. 2013 Dec;38(6):512-7. doi: 10.1111/jcpt.12098. Epub 2013 Sep 16.

PMID:
24102384
11.

Carcinogenicity and chronic rodent toxicity of the selective progesterone receptor modulator ulipristal acetate.

Pohl O, Harvey PW, McKeag S, Boley SE, Gotteland JP.

Curr Drug Saf. 2013 Apr;8(2):77-97.

PMID:
23656453
12.

Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day.

Pohl O, Osterloh I, Gotteland JP.

J Clin Pharm Ther. 2013 Aug;38(4):314-20. doi: 10.1111/jcpt.12065. Epub 2013 Apr 3.

PMID:
23550906
13.

A 39-week oral toxicity study of ulipristal acetate in cynomolgus monkeys.

Pohl O, Williams AR, Bergeron C, Gotteland JP.

Regul Toxicol Pharmacol. 2013 Jun;66(1):6-12. doi: 10.1016/j.yrtph.2013.02.013. Epub 2013 Mar 7.

PMID:
23474274
14.

Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole.

Pohl O, Osterloh I, Lecomte V, Gotteland JP.

Int J Clin Pharmacol Ther. 2013 Jan;51(1):26-33. doi: 10.5414/CP201789.

PMID:
23110788
15.

Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model.

Colette S, Defrère S, Lousse JC, Van Langendonckt A, Gotteland JP, Loumaye E, Donnez J.

Hum Reprod. 2011 Jun;26(6):1362-70. doi: 10.1093/humrep/der079. Epub 2011 Mar 25.

PMID:
21441545
16.

Characterization of immune cell subsets during the active phase of multiple sclerosis reveals disease and c-Jun N-terminal kinase pathway biomarkers.

Ferrandi C, Richard F, Tavano P, Hauben E, Barbié V, Gotteland JP, Greco B, Fortunato M, Mariani MF, Furlan R, Comi G, Martino G, Zaratin PF.

Mult Scler. 2011 Jan;17(1):43-56. doi: 10.1177/1352458510381258. Epub 2010 Sep 20.

PMID:
20855355
17.

Kit ligand and the somatostatin receptor antagonist, BIM-23627, stimulate in vitro resting follicle growth in the neonatal mouse ovary.

Gougeon A, Delangle A, Arouche N, Stridsberg M, Gotteland JP, Loumaye E.

Endocrinology. 2010 Mar;151(3):1299-309. doi: 10.1210/en.2009-0762. Epub 2010 Jan 7.

PMID:
20056831
18.

AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils.

Carboni S, Boschert U, Gaillard P, Gotteland JP, Gillon JY, Vitte PA.

Br J Pharmacol. 2008 Jan;153(1):157-63. Epub 2007 Nov 19.

19.

Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice.

Gómez-Sintes R, Hernández F, Bortolozzi A, Artigas F, Avila J, Zaratin P, Gotteland JP, Lucas JJ.

EMBO J. 2007 Jun 6;26(11):2743-54. Epub 2007 May 17.

20.

A cellular assay for measuring the modulation of glucose production in H4IIE cells.

de Raemy-Schenk AM, Troublé S, Gaillard P, Page P, Gotteland JP, Scheer A, Lang P, Yeow K.

Assay Drug Dev Technol. 2006 Oct;4(5):525-33.

PMID:
17115923
21.

A cellular assay for measuring the inhibition of glycogen synthase kinase-3 via the accumulation of beta-catenin in Chinese hamster ovary clone K1 cells.

Yeow K, Novo-Perez L, Gaillard P, Page P, Gotteland JP, Scheer A, Lang P.

Assay Drug Dev Technol. 2006 Aug;4(4):451-60.

PMID:
16945017
22.

Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.

Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, Chabert C, Church D, Cirillo R, Gretener D, Halazy S, Nichols A, Szyndralewiez C, Vitte PA, Gotteland JP.

J Med Chem. 2005 Jul 14;48(14):4596-607.

PMID:
15999997
23.
24.

Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase.

Rückle T, Biamonte M, Grippi-Vallotton T, Arkinstall S, Cambet Y, Camps M, Chabert C, Church DJ, Halazy S, Jiang X, Martinou I, Nichols A, Sauer W, Gotteland JP.

J Med Chem. 2004 Dec 30;47(27):6921-34.

PMID:
15615541
25.

Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats.

Ferrandi C, Ballerio R, Gaillard P, Giachetti C, Carboni S, Vitte PA, Gotteland JP, Cirillo R.

Br J Pharmacol. 2004 Jul;142(6):953-60. Epub 2004 Jun 21.

26.

AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties.

Carboni S, Hiver A, Szyndralewiez C, Gaillard P, Gotteland JP, Vitte PA.

J Pharmacol Exp Ther. 2004 Jul;310(1):25-32. Epub 2004 Feb 26.

27.

Sulfonamide derivatives of benzylamine block cholesterol biosynthesis in HepG2 cells: a new type of potent squalene epoxidase inhibitors.

Gotteland JP, Loubat C, Planty B, Junquéro D, Delhon A, Halazy S.

Bioorg Med Chem Lett. 1998 Jun 2;8(11):1337-42.

PMID:
9871762
28.

(Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors.

Gotteland JP, Brunel I, Gendre F, Désiré J, Delhon A, Junquéro D, Oms P, Halazy S.

J Med Chem. 1995 Aug 18;38(17):3207-16.

PMID:
7650673

Supplemental Content

Loading ...
Support Center